Insight

Jul 29, 2024, 02:27

Leandro Jonata Oliveira: Would you recommend universal germline GT for patients with cancer?

Leandro Jonata Oliveira, Medical Oncologist at Grupo Oncoclinicas, shared a poll on X:

“Tapestry Study: screening using exome Sequencing identified 32% of HBOC and 56% of Lynch Syndrome carriers who did not meet NCCN criteria for genetic testing (GT).

In the scenario of unrestricted access to GT and couseling, would you recommend universal germline GT for patients with cancer?

Yes
Not
Not yet

‘Exome Sequencing Identifies Carriers of the Autosomal Dominant Cancer Predisposition Disorders Beyond Current Practice Guideline Recommendations published in JCO Precision Oncology’

Autors: N. Jewel Samadder, Emily Gay, Vanda Lindpere, Michelle L. Bublitz, Lorelei A. Bandel, Sebastian M. Armasu, Robert A. Vierkant, Matthew J. Ferber, Eric W. Klee, Nicholas B. Larson, Teresa M. Kruisselbrink, Jan B. Egan, Jennifer L. Kemppainen, Jessa S. Bidwell, Jennifer L. Anderson, Tammy M. McAllister, T’Nita S. Walker, Katie L. Kunze, Michael A. Golafshar, Margaret A. Klint, Richard J. Presutti, William V. Bobo, Aleksander Sekulic, Jolene M. Summer-Bolster, Cheryl L. Willman, and Konstantinos N. Lazaridis.”

Leandro Jonata Oliveira

Source: Leandro Jonata Oliveira/X

Aleksander Sekulic cancer Cheryl L. Willman Emily Gay Eric W. Klee exome Sequencing identifies Jan B. Egan Jennifer L. Anderson Jennifer L. Kemppainen Jessa S. Bidwell Jolene M. Summer-Bolster Katie L. Kunze Konstantinos N. Lazaridis Leandro Jonata Oliveira Lorelei A. Bandel Lynch Syndrome Margaret A. Klint Matthew J. Ferber Michael A. Golafshar Michelle L. Bublitz N. Jewel Samadder NCCN Nicholas B. Larson OncoDaily Oncology Richard J. Presutti Robert A. Vierkant Sebastian M. Armasu T'Nita S. Walker Tammy M. McAllister Teresa M. Kruisselbrink Vanda Lindpere William V. Bobo

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial